Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
BioFocus is expanding its Huntingdon’s disease collaboration with CHDI by committing to take targets it developed in its earlier deal, through discovery as part of a five year, $41m (€31m) agreement.
Galapagos' services arm has scored another lucrative contract from
big pharma - its first in the field of oncology - as it continues
to broaden its experience.
GlaxoSmithKline (GSK) is the latest drug firm to involve Galapagos
in a new development partnership, in a deal worth up to €218m for
the Belgian biotech.
Galapagos' recent acquisitions seem to be paying off as the Belgian
biotech firm has announced its contract services unit BioFocus DPI
has inked two new deals with Japan-based Ono Pharmaceutical.
Belgium genomics company Galapagos has put in place another element
in its strategy to develop in-house drug products functions with
the appointment of a new chief scientific officer.
Galapagos Genomics has published details of its RNAi-based gene
silencing technology, based on adenovirus vectors, that is
effective in a range of cell types.